title: [41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece].
authors.affiliation: Département de Médecine Interne, Centre Hospitalier de Béziers, France. bernard.simorre@ch-beziers.fr
authors.forename: B
authors.initials: B
authors.lastname: Simorre
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000188:drug therapy; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000503:physiopathology / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D000077205:Pioglitazone; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D050071:Bone Density Conservation Agents; D004232:Diuretics; D007004:Hypoglycemic Agents; D000451:Mineralocorticoid Receptor Antagonists; D045162:Thiazolidinediones; D013148:Spironolactone; D020849:Raloxifene Hydrochloride; D000077205:Pioglitazone